title: Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up.
abstract: BACKGROUND
  Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+, K+-ATPase, necessary for the final step in gastric acid secretion.
  
  
  OBJECTIVE
  To assess safety and efficacy of oral pantoprazole (40 mg o.d.) used as a prophylaxis against relapse in patients with healed reflux oesophagitis during an open-label, 2-year study.
  
  
  METHODS
  Outpatients (n=157) with healed stage II or III reflux oesophagitis (Savary-Miller classification) were enrolled into a long-term, multicentre maintenance study. Endoscopy was performed at entry into the study, after 12 and 24 months, or when disease-specific symptoms occurred on more than three consecutive days. Symptoms were assessed at 3-monthly intervals. Endoscopically confirmed relapses (at least stage I) were evaluated as treatment failures.
  
  
  RESULTS
  Of the 178 adverse events, experienced by 88 (56%) patients (intention-to-treat population), 12 (7%) were assessed by the investigators as possibly related to the study medication. Median serum gastrin levels increased from a baseline of 46 ng/L to 90 ng/L, reaching a plateau after 9 months. For the intention-to-treat population the endoscopic remission rates after 12 and 24 months were 87% and 76%, respectively (Life-Table survival analysis, Kaplan-Meier).
  
  
  CONCLUSIONS
  Pantoprazole 40 mg proved to be safe and efficacious during a 2-year prophylaxis treatment in patients with healed reflux oesophagitis.
authors.affiliation: Gastroenterology Units of University of Stellenbosch, South Africa. christoj@masa.co.za
authors.forename: C J
authors.initials: CJ
authors.lastname: Van Rensburg
authors.forename: P J
authors.initials: PJ
authors.lastname: Honiball
authors.forename: J H
authors.initials: JH
authors.lastname: Van Zyl
authors.forename: H D
authors.initials: HD
authors.lastname: Grundling
authors.forename: F P
authors.initials: FP
authors.lastname: Eloff
authors.forename: S K
authors.initials: SK
authors.lastname: Spies
authors.forename: A E
authors.initials: AE
authors.lastname: Simjee
authors.forename: I
authors.initials: I
authors.lastname: Theron
authors.forename: R
authors.initials: R
authors.lastname: Fischer
authors.forename: J A
authors.initials: JA
authors.lastname: Louw
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors; D012008:Recurrence; D013454:Sulfoxides / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D000077402:Pantoprazole; D009853:Omeprazole